Alixorexton at all doses demonstrated significant improvements from baseline in mean sleep latency compared with placebo. The Food and Drug Administration (FDA) has granted Breakthrough Therapy ...

CHICAGO -- Novel orexin receptor 2 agonist oveporexton normalized wakefulness for most people with narcolepsy type 1 in two randomized phase III trials. Mean sleep latency across four, 40-minute ...

– Alixorexton Demonstrated Clinically Meaningful and Statistically Significant Improvements in Wakefulness at All Doses Tested Compared to Placebo in Patients With Narcolepsy Type 1 – – Alixorexton ...

Earlier this month, Alkermes plc announced that the FDA granted Breakthrough Therapy designation to alixorexton, its oral selective orexin 2 receptor agonist, for narcolepsy type 1 based on positive ...

Narcolepsy with cataplexy, now known as type 1 narcolepsy, is a chronic neurological disorder that affects a person’s sleep-wake cycle and involves muscle weakness. The condition can cause a person to ...

(RTTNews) - Alkermes plc (ALKS), a biopharmaceutical company, on Tuesday reported that the U.S. Food and Drug Administration has granted Breakthrough Therapy designation to Alixorexton for the ...

– First Orexin 2 Receptor Agonist to Demonstrate Clinically Meaningful and Statistically Significant Impact on Wakefulness, Cognition and Fatigue with Once-Daily Dosing Across a Range of Doses – – ...

Ron Grunstein, MD, PhD, head of sleep and circadian research, Woolcock Institute of Medical Research, details results from the ALKS 2680 trial and the study's next steps. In part 2 of his interview, ...

DUBLIN--(BUSINESS WIRE)-- Alkermes plc (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to alixorexton for the treatment of ...